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Abstract
Background: Lithuania is a country with a high incidence of tuberculosis (TB), despite a high
coverage with bacille Calmette-Guerin (BCG) vaccination. Until now the only method used to
detect latent TB infection was the tuberculin skin test (TST). However, TST may have a cross
reactivity to the BCG vaccine and to environmental mycobacteria. The aim of this study was to
conduct assessments of the diagnostic accuracy of the T-cell based test (T SPOT TB) for TB in
children who had previously been BCG vaccinated and compare these with the results of the TST.
Methods: Between January 2005 and February 2007, children with bacteriologically confirmed TB,
children having contacts with a case of infectious pulmonary TB and children without any known
risk for TB were tested with both the TST and T SPOT TB.
Results: The TST and T SPOT TB tests were positive for all patients in the „culture-confirmed
TB“ group. Whereas, in the „high risk for TB“ group, the TST was positive for 60%, but the T SPOT
TB test, only for 17.8%. Meanwhile the results for the „low risk for TB“ group were 65.4% and
9.6%, respectively. A correlation between the TST and T SPOT TB was obtained in the "culture-
confirmed TB" group where the TST ≥15 mm (r = 0.35, p < 0.001).
Conclusion: The T-cell based method is more objective than the TST for identifying latent TB
infection in children who had been previously BCG vaccinated. This method could be useful in
countries like Lithuania where there is a high incidence of TB despite a high coverage with BCG
vaccination. It may also help to avoid unnecessary chemoprophylaxis when TST reactions are false-
positive.
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Rapid identification and adequate treatment of latent
tuberculosis (TB) infection is a very important part of suc-
cessful TB control [1]. Any person, especially a child, who
is exposed to infectious pulmonary TB, has a high risk of
getting a TB infection or disease [2]. Even in countries
with a low prevalence of TB, 3040% of the new cases are
caused by the transmission of Mycobacterium tuberculosis
from infectious cases [3,4].
Lithuania is a country of high incidence of TB despite a
high coverage with bacille Calmette-Guerin (BCG) vacci-
nation. In Lithuania the prevalence of TB doubled
through 19901997; it has stabilized since 1998. The TB
incidence rate ranges from 6070/100,000 inhabitants
[5,6]. Nevertheless, according to a national anti-TB drug
resistance prevalence survey, an alarmingly high preva-
lence of drug-resistant TB is challenging Lithuania- by
about 9% of new TB cases [6,7].
Since 1890, and until recently, the only method available
for the detection of latent TB infection was the tuberculin
skin test (TST). However, it has poor specificity, especially
in the population vaccinated with BCG [2,4,8]. The
hypothesis is that a repetition of the TST may induce a
booster effect [9]. The TST may have a cross reactivity to
the BCG vaccine and to environmental mycobacteria
[4,8]. If a TST shows a false-positive reaction, the subject
does not have TB. Nonetheless, potentially unnecessary
treatment will be administered to that subject. It is known
that an irrational treatment of active TB may be a factor
predisposing anti-TB drug resistance [7]. Unnecessary che-
moprophylaxis can induce a hepatotoxic effect.
Newly developed blood tests are based on the detection of
interferon-gamma (INF-γ) secretion by T-cells in response
to Mycobacterium tuberculosis antigens: early secreted anti-
genic target (ESAT-6) and culture filtrate proteins (CFP-
10). These tests could constitute a more rapid, specific and
sensitive method for detection of TB infection [2,4,8,10].
T-cell-based tests are not affected either by a prior BCG
vaccination or by most environmental mycobacteria. Fur-
thermore, they were recently integrated into certain guide-
lines of strategies for screening subjects exposed to TB
[11,12]. The T SPOT TB is one of the new, T-cell-based
tests for TB infection, the approved regulatory version of
the ex vivo enzyme-linked immunospot assay. The aim of
our study was to conduct assessments regarding the diag-
nostic accuracy of the T SPOT TB for TB in children in
Lithuania and to compare these with the results from the
TST in the same population.
Methods
Between January 2005 and February 2007, patients (aged
1017 years old) with TB, the subjects screened for having
contact with a case of infectious pulmonary TB and the
subjects without any known risk for TB who were seeking
a prophylactic examination at the Department of Pediatric
Diseases, Kaunas Medical University Hospital were pro-
spectively invited to participate in this study. The study
protocol was approved by the Regional Bioethics Com-
mittee of the Kaunas University of Medicine and written
informed consent was obtained from all participants and/
or their parents.
All study subjects were divided into the following three
groups:
1) „Culture-confirmed TB“ group (n = 23)  these are
subjects with a bacteriologically confirmed TB diagno-
sis.
2) „High risk for TB“ group (n = 45)  these are subjects
living with a family member who is ill with infectious
TB or having contact with such a person in their
school-classes. The shortest time of exposure was 5
weeks. All subjects in this group were free of symp-
toms at the time of enrolment.
3) „Low risk for TB“ group (n = 52)  these are subjects
with no identifiable risk for TB (no known history of
contact with TB patient, no changes in X-ray nor any
complaints).
All subjects were screened using chest radiography, a clin-
ical examination and an interview regarding their history
of exposure to TB. All of the studied subjects had been
BCG vaccinated in the past (at their birth and 7 yrs)
according to the Government's Health Programme recom-
mendations of that time [13]. BCG status was determined
by scar after vaccination. None of these subjects had
received an anti-TB treatment in the past. None had symp-
toms of HIV infection nor were suspected of carrying HIV
and all were from a population at a low risk for HIV.
Eight patients from the „culture-confirmed TB“ group
who had provided consent were repeatedly tested with
TST and T-SPOT. TB after 8 weeks of treatment with iso-
niasid, rifampicin, ethambutol and pyrazinamide in
doses administered according to their weight.
Tuberculin skin test (TST)
The TST was performed according to the Mantoux tech-
nique by using 2 units (bioequivalent to 5 units as per the
international standard) of the purified protein derivative,
PPD (Copenhagen Statens Serum Institute, Denmark).
The transverse diameter of induration was measured after
72 hours by a well-trained staff. The TST reaction was con-
sidered positive when the induration was ≥10 mm [14].Page 2 of 8
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Before the TST testing 10 ml of a venous blood was drawn
for the diagnostic test of Mycobacterium tuberculosis-spe-
cific IFN-γ secreting T-cells (T SPOT TB, Oxford Immu-
notec, Oxford, UK). The T SPOT TB test was performed
using fresh blood (<5 hours at room temperature) accord-
ing to the manufacturer's instructions. These tests were
done in the laboratory of the Kaunas Medical University
Hospital. The mononuclear cells from peripheral blood
were seeded at 2.5 × 105 cells/well in single-well plates,
and two separate pools of overlapping peptides spanning
the full length of ESAT-6 and CFP-10 proteins were used
together with the negative and positive controls. The indi-
vidual spots were counted for ESAT-6 and CFP-10 by
using manual counting with Trypan Blue and a haemocy-
tometer. The responses were considered as positive when
the number of spots in the test wells (against at least one
of the two tested antigens) was ≥6, if the negative control
had 05 spots, or ≥2× the number of spots in the negative
control wells, if the negative control had 610 spots. This
cutoff was predefined by the manufacturer's instructions
and previous publications [15,16].
Statistical analysis
The data were analyzed using the SPSS package for Win-
dows 13. Descriptive statistics were used for rating single
characteristics. The Student's T test was performed to
determine significance levels. Comparisons between
numbers of spots in the T SPOT TB test and the TST diam-
eters of induration were performed using the non-para-
metric Mann-Whitney-Wilcoxon rank sum test and
Kruskal-Wallis test for comparison of more than two
groups. Kendall's rank correlation was used to measure
the strength of dependence between two variables. The
results are presented as the mean ± standard deviation
(SD). The level was considered significant at p < 0.05.
Results
One hundred and twenty subjects agreed to be included in
this study. The characteristics of the studied subjects are
presented in Table 1. The demographic characteristics of
the subjects did not differ significantly. The BCG vaccina-
tion rate of the studied subjects was 100%. TST and T
SPOT TB were performed to all the studied subjects under
study thereby providing valuable results. The distribution
of the TST and T SPOT TB results in the studied groups is
presented in Table 2.
All patients from the „culture-confirmed TB“ group
showed a positive TST and had a positive T SPOT TB test
indicating a sensitivity of 100%. In that group, 82.6% of
subjects showed an induration ≥15 mm in the TST.
Comparatively, of the total 45 subjects in the „high risk
for TB“ group, 27 (60%) showed a positive TST, but only
8 (17.8%) had a positive T SPOT TB test. Seven of the 8 T
SPOT TB-positive subjects from the „high risk for TB“
group had TST with ≥10 mm induration, and one had TST
with <10 mm induration. In the „low risk for TB“ group,
the prevalence of positive TST and T SPOT TB tests was
65.4% and 9.6%, respectively (Tables 1 and 2). The prev-
alence of positive TST and positive T SPOT TB tests was
significantly higher in the „culture-confirmed TB“ group.
The mean size of the TST induration and the T SPOT TB
spot counts also prevailed in this group, but did not differ
significantly between the other two groups.
The number of spots to ESAT-6 (T SPOT TB panel A) did
not differ significantly from the spots count to CFP-10 (T
SPOT TB panel B) in each group. However, they were sig-
nificantly higher in the „culture-confirmed TB“ group
than in the groups without clinical signs of TB (Figure 1).
The results of TST (induration in mm) in relation to the
Table 1: Characteristics of studied subjects and results of TST and T SPOT TB test
Groups
Variables Culture-confirmed TB High risk for TB Low risk for TB
Subjects n 23 45 52
male 52.2 42.2 53.8
Sex, % female 47.8 57.8 46.2
Age, yrs† 15.1 (2.3) 14.0 (1.7) 13.3 (2.3)
TST size (mm) † 18.0 (3.4)* 8.7 (6.1) 10.0 (7.2)
T SPOT TB spot counts† 35.0 (22.5)* 3.0 (5.4) 2.9 (4.4)
†- data are presented as mean (SD)
*- p < 0.001 vs other groupsPage 3 of 8
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Figure 2.
Subjects with both a positive TST and a positive T SPOT TB
test (7 from the „high risk for TB“ group and 3 from the
„low risk for TB“ group) were considered as being infected
with Mycobacterium tuberculosis. One of the 18 TST-nega-
tive subjects from the „high risk for TB“ group and 2 of the
18 TST-negative subjects from the „low risk for TB“ group
reacted positively in the T SPOT TB test. The reason of this
discrepancy is unclear.
Because the cutoff for the TST is questionable, an attempt
was made to analyze the T SPOT TB responses in relation
to TST by applying different cutoffs. Depending on the
TST cutoff, the studied subjects were divided into the fol-
lowing four groups: TST <5 mm, TST ≥5 and <10 mm, TST
≥10 and <15 mm, and TST ≥15 mm. The numbers of pos-
itive T SOPT TB subjects based on the four different TST
cutoff values are presented in Table 3. A significant corre-
lation between the TST and T SPOT TB tests was obtained
in the "culture-confirmed TB" group where TST ≥15 mm
(r = 0.35, p < 0.001).
Furthermore, an investigation of the influence of anti-TB
treatment on TST and T SPOT TB test results was con-
ducted for this study. Eight children from the "culture-
confirmed TB" group were repeatedly investigated after 8
weeks of anti-TB treatment. The TST results were still pos-
itive after the treatment (TST induration 17.9 ± 3.9 mm
before treatment and 16.0 ± 3.5 mm after treatment).
However, the number of T SPOT TB spot counts was
reduced significantly after the treatment (no. of spots 50.3
± 11.2 vs 9.8 ± 2.3 respectively, p = 0.01) (Figure 3). After
8 weeks of the anti-TB treatment, positive T SPOT TB
results reverted in 5/8 children from the "culture-con-
firmed TB" group; whereas, in 3 children (with proven
multidrug-resistant TB) the T SPOT TB test was still posi-
tive.
Discussion
This study reports the results of the first evaluation of ex
vivo INF-γ-based assay (T SPOT TB) for the diagnosis of TB
Table 2: Distribution of T SPOT TB and TST in studied groups
Culture confirmed TB
(n = 23)
High risk for TB
(n = 45)
Low risk for TB
(n = 52)
T SPOT TB (+)
TST (+)
23* 7 3
T SPOT TB (+)
TST (-)
0 1 2
T SPOT TB (-)
TST (+)
0 20 31
T SPOT TB (-)
TST (-)
0 17 16
-, negative; +, positive;
*- p < 0.001 vs other groups
Distribution of T SPOT TB results in relation to the studied groups and antigens usedFig re 1
Distribution of T SPOT TB results in relation to the 
studied groups and antigens used. The comparison was 
performed considering only positive T SPOT TB results. The 
numbers of spots to ESAT-6 (T SPOT TB panel A) and CFP-
10 (T SPOT TB panel B) in the „culture-confirmed TB“ group 
were significantly higher than in other groups (p < 0.001), but 
























G r o u p s
ESAT-6 (panel A)
CFP-10 (panel B)Page 4 of 8
(page number not for citation purposes)
BMC Pulmonary Medicine 2009, 9:41 http://www.biomedcentral.com/1471-2466/9/41infection in children in a country of a high incidence of TB
despite a high coverage with BCG vaccination, and
presents the comparison of T SPOT TB results with those
of the TST. In this study we found that 100% of the chil-
dren with a bacteriologically confirmed TB diagnosis had
both a positive T SPOT TB and TST. However, the preva-
lence of positive TST in the studied children at a "high risk
for TB" and in the children at a "low risk for TB" was sig-
nificantly higher than the prevalence of positive T SPOT
TB results was in the same groups. A striking observation
was that 70% of the studied children from all three groups
had a positive TST and only 39% of children with a posi-
tive TST had a positive T SPOT TB.
There is no gold standard for the diagnosis of latent TB
infection [17,18]. TST is routinely used as the first step in
the diagnosis of TB infection. According to the results of
this study, the prevalence of positive TST is high, even in
the "low risk for TB" group. TST may be false-positive in
many cases of studied children, since the coverage of BCG
vaccination in our country is high. All the studied children
had a BCG vaccination in early childhood (at their birth
and 7 yrs). Previous studies have shown that the TST does
not accurately reflect the risk of latent TB infection in a set-
ting with extensive BCG coverage [12,19,20]. There is a
hypothesis that repetition of TST may induce a booster
effect [9]. The specificity of TST may be not adequate due
to cross-reactions not only with BCG vaccination, but also
with non-tuberculous mycobacteria which appears to be
Box and whisker plot of TST induration (in mm) in relation to the positive and negative T SPOT TB responsesFigure 2
Box and whisker plot of TST induration (in mm) in relation to the positive and negative T SPOT TB responses. 
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Table 3: The numbers of positive T SOPT TB subjects based on the four different TST cutoff values
No. of persons TST <5 mm TST 59 mm TST 1014 mm TST ≥15 mm
Culture-confirmed TB 0/0 0/0 4/4 19/19
High risk for TB 0/12 1/6 4/16 3/11
Low risk for TB 2/16 0/2 0/13 3/21
Data are presented as n (of subjects with a positive T SPOT TB)/n (of subjects with defined TST cutoff value)Page 5 of 8
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tant to note that false-positive TST reactions may lead to
unnecessary treatment [16,22]. Chemoprophylaxis of TB
infected persons is an important component of TB control
strategy; however, due to the significant risk of hepatotox-
icity and other side effects of anti-TB treatment, chemo-
prophylaxis cannot be prescribed only on the basis of the
TST [8,10,23], especially in children.
In this study, all the children with a bacteriologically con-
firmed TB diagnosis had a positive T SPOT TB test. Other
studies using the same assay system also demonstrated
sensitivity values of 90% and 100% [15,24]. Various stud-
ies have shown that the T SPOT TB is more, rather than
less, sensitive test than is the TST [2,8]. Moreover, the
extremely high correlation of the TST with the BCG vacci-
nation showed that false-positive reactions to the TST are
rather than false-negative reactions to the T SPOT TB test
[8]. However, there are also studies demonstrating the dis-
cordant results. Some of the studies, mainly performed
with the other T-cell-based test QuantiFERON-TB (QFT),
showed a fairly high level of negative results even among
patients with active TB [25]. Antigens ESAT-6 and CFP-10
are specific for Mycobacterium tuberculosis, but they do not
represent all antigenicity of Mycobacterium tuberculosis
[26]. Lighter et al. studied 207 children with the TST and
QFT, and found an excellent correlation between the neg-
ative TST and negative QFT results; however, only 23% of
the studied children with a positive TST had a positive
QFT [27]. Kang et al. found the positive QFT rates 4%,
10%, 44% and 81% in low risk, casual contact, close con-
tact, and active TB patients, respectively [25]. Whereas in
our study, the positive T SPOT TB results were: 9.6%,
17.8% and 100% in low risk, high risk for TB and bacteri-
ologically confirmed TB groups. Such discrepancy
between the results could be explained by the different
distribution of patients to the groups (we did not differen-
tiate TB-contacts), also by the different status of BCG vac-
cination. In our study, 100% of studied children showed
a BCG scar, whereas in the Korean study only 67% from
TB-close contacts had such scar; that is why they could be
more susceptible for TB infection.
Despite affirmation by the subjects from the "low risk for
TB" group that they had no known contact with a TB-sick
person, 3 of them showed positive TST and T SPOT TB
test. This fact caused a question about some unknown
exposure to infectious pulmonary TB. There is a possible
limitation to this present study that should be mentioned.
The subjects enrolled into the study were actively seeking
a prophylactic examination; they were not part of a ran-
domly selected population. All subjects without clinical
signs of TB, but with both positive TST and T SPOT TB
tests were considered as having latent TB infection. This
definition was arbitrary. Indeed, as mentioned before,
there is no gold standard for defining latent TB infection
[17,18].
Three from studied children with a negative TST test
showed a positive T SPOT TB test. The reason of that is
unclear. Children with a negative TST and a positive T
SPOT TB may have a false-negative TST due to an intercur-
rent viral infection. Or, the possible explanation of this
discrepancy would be that the T SPOT TB results were false
positive or that the subjects were truly infected with Myco-
bacteria tuberculosis or another ESAT-6 or CFP-10 contain-
ing non-TB mycobacteria [8,19]. Franken et al. reported
that 41% of the studied subjects with negative TST results
in association with positive T SPOT TB assay (mainly to
CFP-10) one year later had converted to positive TST
results in association with negative T SPOT TB results [28].
In previous studies, it has been postulated that the
response to the CFP-10 antigen might be indicative of
active replication of the bacteria; whereas, the responses
to the ESAT-6 antigen may persist as an immunological
"scar" [28,29]. Further studies are needed to gain a better
understanding of this phenomenon. In this study, the
number of spots to ESAT-6 did not significantly differ
from the count of spots to CFP-10. However, in children
with confirmed-TB, the ESAT-6 and CFP-10 were signifi-
cantly higher than they were in the TST-positive or TST-
negative children from the other groups.
Furthermore, we have also analyzed the T SPOT TB
responses in relation to TST using different cutoffs,
because a TST cutoff ≥5 mm for contacts who have been
previously BCG vaccinated is questionable [3,16]. All chil-
Change of T SPOT TB results after 8-weeks anti-tuberculosis (TB) therapy in culture-confirmed TB subjectsFigur 3
Change of T SPOT TB results after 8-weeks anti-
tuberculosis (TB) therapy in culture-confirmed TB 
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mm. Agreement between the TST and T SPOT TB results
was obtained only in children with culture-confirmed-TB
when the TST was ≥15 mm, but the discordance between
these tests in other children shows that they are not equiv-
alent. As many as 51 of the 61 individuals (83.6%) from
the "high risk for TB" and "low risk for TB" groups with a
TST reaction ≥10 mm were T SPOT TB negative. Data from
this and previous studies confirm the lower sensitivity of
TST compared to the INF-γ assay [16,22,30,31]. Even with
an increased cut-off for the TST of 15 mm induration, 26
of the children from these groups would still have been
indicated for chemoprophylaxis though their T SPOT TB
tests were negative. Chee et al. also analysed levels of
agreement between the TST and the INF-γ assay, but using
a 15 mm induration cutoff for the TST did not make a sub-
stantial difference to the test results [29].
During the 8-weeks anti-TB treatment of children with
culture-confirmed TB, the number of spots in the T SPOT
TB test declined markedly; whereas, anti-TB treatment did
not influence the TST results. Three children (from 8)
treated with anti-TB drugs were still positive in their T
SPOT TB tests after treatment. The reason why these chil-
dren still had a high degree of positivity in their T SPOT
TB tests may be linked with the persistence of a high bac-
teriological load as they had the multidrug-resistant form
of TB. In previous studies, it was also shown that, in
patients responding to therapy, the number of TB-specific
T cells can decline below the cutoff value after 3 months
[4,15,32]. All these data permits a suggestion that the INF-
γ assay could be useful for monitoring the efficacy of TB
therapy.
The data of this study show that the INF-γ-based method
(like the T SPOT TB) is more objective and accurate than
the TST for identifying latent TB infection in children.
Since in our country with high coverage of BCG vaccina-
tion, where TST is currently the only tool routinely used
for detecting latent TB infection, the false-positive TST
reactions may lead to potentially unnecessary preventive
treatment. This also may lead to incorrect statistical data
regarding latent TB cases. The INF-γ-based assay could be
a very useful addition to the diagnostic algorithm for chil-
dren with suspected TB and may help to avoid unneces-
sary chemoprophylaxis.
Conclusion
The T-cell-based method is more objective than the TST
for identifying latent TB infection in children, especially
in countries like Lithuania which have a high incidence of
TB despite a high coverage with BCG vaccination. This
may also help to avoid unnecessary chemoprophylaxis
when TST reactions are false-positive.
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